10058-F4: Small-Molecule c-Myc Inhibitor for Apoptosis and Cancer Research

Principle Overview: Disrupting c-Myc/Max for Targeted Research

The oncogenic transcription factor c-Myc orchestrates a wide spectrum of cellular processes, from proliferation to metabolic reprogramming, making it a central player in cancer biology. The formation of the c-Myc-Max heterodimer is essential for c-Myc’s transcriptional activity. 10058-F4—a novel, cell-permeable small-molecule c-Myc-Max dimerization inhibitor—selectively disrupts this protein–protein interaction. By abrogating c-Myc/Max heterodimerization, 10058-F4 blocks c-Myc-driven transcriptional programs, resulting in inhibition of cell proliferation, induction of cell cycle arrest, and activation of the mitochondrial apoptosis pathway.

This mechanism is particularly impactful in acute myeloid leukemia (AML) and prostate cancer research, where c-Myc dysregulation drives disease progression. The compound’s value extends to telomerase regulation: c-Myc is a key activator of TERT, the catalytic subunit of telomerase, linking 10058-F4’s action to studies on stem cell maintenance and oncogenic immortality. Recent work, such as the study by Stern et al. (bioRxiv 2024), highlights the interplay between DNA repair, TERT expression, and transcriptional regulation—an axis where c-Myc inhibition offers unique experimental opportunities.

Experimental Workflow: Stepwise Integration of 10058-F4

1. Compound Handling and Preparation

• Solubility: 10058-F4 is highly soluble in DMSO (≥24.9 mg/mL) and ethanol (≥2.64 mg/mL), but insoluble in water. Prepare concentrated stock solutions in DMSO, aliquot, and store at -20°C. Avoid repeated freeze-thaw cycles; use solutions promptly for maximal activity.
• Working Dilutions: For in vitro assays, dilute stocks directly into pre-warmed culture media to achieve final concentrations (commonly 25–100 μM). Maintain final DMSO content ≤0.1% to minimize cytotoxicity.

2. Cell-Based Assays: Apoptosis and Proliferation

• Model Selection: AML cell lines (HL-60, U937, NB-4) and prostate cancer lines (DU145, PC-3) are validated models for 10058-F4 studies.
• Treatment Regimen: Dose cells (e.g., 1–2 x 10⁵ cells/mL) with 10058-F4 at 25, 50, and 100 μM. Incubate for 24–72 hours. Notably, significant apoptosis induction is observed at 100 μM after 72 hours in AML models, as quantified by Annexin V/PI staining and flow cytometry.
• Control Groups: Include vehicle controls (DMSO only) and, if possible, a positive apoptosis-inducing agent for benchmarking.

3. Mechanistic Readouts

• Apoptosis Assays: Assess early and late apoptosis by flow cytometry (Annexin V/PI), caspase-3/7 activity assays, and mitochondrial membrane potential (JC-1 dye).
• c-Myc/TERT Pathway Analysis: Quantify c-Myc and TERT mRNA/protein levels via qPCR and Western blotting. Evaluate mitochondrial apoptosis effectors (e.g., Bcl-2 family proteins, cytochrome C release) to confirm pathway engagement.
• Cell Cycle Arrest: Propidium iodide DNA staining and flow cytometry identify G1/S arrest commonly induced by c-Myc inhibition.

4. In Vivo Applications

• Xenograft Models: For translational studies, administer 10058-F4 intravenously to SCID mice bearing human prostate cancer xenografts. Monitor tumor volume over 2–4 weeks. The compound exhibits variable yet significant tumor growth inhibition in DU145 and PC-3 xenografts.
• Pharmacokinetics: Due to rapid metabolism, repeated dosing or formulation adjustments may be necessary to sustain effective plasma concentrations.

Advanced Applications and Comparative Advantages

1. Dissecting c-Myc/TERT Regulatory Networks

10058-F4’s utility extends beyond apoptosis induction. By inhibiting c-Myc-driven TERT expression, it enables researchers to interrogate telomerase regulation in both cancer and stem cell models. This is particularly relevant in light of recent findings by Stern et al. (2024), where TERT regulation was shown to involve DNA repair enzyme APEX2; using 10058-F4 in tandem with APEX2 knockdown can clarify the hierarchical relationship between oncogenic transcription factors and telomerase control.

2. Integrated Workflows: Apoptosis and DNA Repair Crosstalk

Incorporating 10058-F4 into multi-parametric assays—such as combining apoptosis detection with DNA damage response markers (γ-H2AX, comet assay)—enables the study of c-Myc’s role in maintaining genomic stability. This can elucidate how c-Myc/Max disruption intersects with the DNA repair machinery and telomerase regulation, complementing studies like those discussed in "Strategically Disrupting c-Myc/Max Dimerization: 10058-F4".

3. Comparative Insights and Literature Integration

• "10058-F4: Unraveling c-Myc/Max Disruption for Apoptosis" complements this workflow by providing detailed strategies for apoptosis quantification and telomerase linkage.
• "10058-F4: Advanced c-Myc-Max Dimerization Inhibitor in Apoptosis and Telomerase Research" offers mechanistic depth on mitochondrial apoptosis, extending the core protocol to broader cellular stress paradigms.
• Together, these resources provide a multi-faceted toolkit for deploying 10058-F4 across diverse cancer and stem cell biology contexts.

4. Data-Driven Performance Benchmarks

• Apoptosis Induction: In AML lines, 10058-F4 at 100 μM induces >40% apoptotic cells after 72 hours, compared to <10% in vehicle controls.
• Tumor Growth Inhibition: SCID mice treated with 10058-F4 show tumor volume reductions of 25–40% versus untreated controls over a 3-week course, with efficacy varying by xenograft model.
• TERT Downregulation: qPCR and immunoblot analyses reveal >60% reduction in TERT expression upon c-Myc inhibition, supporting its use in telomerase regulation studies.

Troubleshooting and Optimization Tips

1. Compound Handling

• Precipitation: If precipitation occurs upon dilution, gently warm and vortex before adding to cells. Always filter sterilize stocks to avoid particulates.
• Degradation: Prepare fresh stocks for each experiment as solutions degrade over time, even at -20°C.

2. Assay Sensitivity and Controls

• Cell Line Variability: Sensitivity to 10058-F4 varies; perform initial dose-response curves and time-course studies to optimize conditions for each model.
• Vehicle Effects: Keep DMSO concentration consistent across all wells; excess DMSO can cause off-target cytotoxicity.

3. Mechanistic Readouts

• Confirming c-Myc Inhibition: Verify c-Myc/Max disruption by immunoprecipitation or proximity ligation assays. Use parallel siRNA knockdown as an orthogonal control.
• Downstream Pathways: Monitor both early (e.g., caspase activation) and late (e.g., DNA fragmentation) apoptosis markers for a complete picture of cell fate.

4. In Vivo Model Considerations

• Pharmacokinetic Challenges: Rapid metabolism may require multiple daily injections or use of slow-release formulations for sustained exposure in animal models.
• Off-Target Effects: Carefully titrate doses and monitor animal health, as high systemic exposure can induce toxicity.

Future Outlook: Expanding the Impact of c-Myc/Max Disruption

The mechanistic precision of 10058-F4 positions it as a critical tool for unraveling oncogenic and stem cell pathways. As research advances in DNA repair and telomerase regulation—highlighted by studies such as Stern et al. (2024)—integration of c-Myc-Max dimerization inhibitors into CRISPR screens, stem cell differentiation protocols, and resistance modeling will further clarify the interplay between transcription, genome maintenance, and cellular longevity.

Researchers looking to harness the full potential of 10058-F4 should stay attuned to cross-disciplinary advances linking apoptosis, DNA repair, and telomerase biology. As a trusted supplier, APExBIO ensures batch-to-batch consistency and validated activity, supporting reproducible results in both exploratory and translational studies. For detailed specifications, protocols, and ordering, visit the 10058-F4 product page.

By strategically deploying this small-molecule c-Myc-Max dimerization inhibitor, researchers can advance not only apoptosis assays and acute myeloid leukemia research, but also the next generation of cancer therapeutics and stem cell interventions.